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Abstract
Objective To examine the extent to which mindfulness
skills influence psychological distress and health-related
quality of life (HRQOL) in men with metastatic or castra-
tion-resistant biochemical progression of prostate cancer.
Patients and methods A cross-sectional survey of 190 men
(46 % response; mean age 71 years, SD = 8.7, range
40–91 years) with advanced prostate cancer, assessed
psychological and cancer-specific distress, HRQOL.
Mindfulness skills were assessed as potential predictors of
adjustment outcomes.
Results Overall, 39 % of men reported high psychological
distress. One third had accessed psychological support pre-
viously although only 10 % were under current
psychological care. One quarter had accessed a prostate
cancer support group in the past six months. Higher HRQOL
and lower cancer-specific and global psychological distress
were related to non-judging of inner experience (p\ 0.001).
Higher HRQOL and lower psychological distress were
related to acting with awareness (p\ 0.001). Lower dis-
tress was also related to higher non-reactivity to inner
experience and a lower level of observing (p\ 0.05).
Conclusions Men with advanced prostate cancer are at risk
of poor psychological outcomes. Psychological flexibility
may be a promising target for interventions to improve
adjustment outcomes in this patient group.
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Introduction
Prostate cancer is the second most frequently diagnosed
cancer in men worldwide, with an estimated 1.1 million
new cases diagnosed in 2012 [1]. It is the fifth most
common cause of cancer death internationally. Incidence
rates vary 25-fold worldwide, with highest rates in Aus-
tralia and New Zealand. An estimated 1 in 5 Australian
men will develop prostate cancer in their lifetime, and 1 in
28 will die of prostate cancer [2]. Approximately, 5–10 %
of newly diagnosed Australian men have locally advanced
or metastatic disease [3, 4]. Although prostate cancer is
generally a slow-growing cancer, recurrence or progression
can develop over the long term, even among patients
considered to have low risk at diagnosis [5]. Further, an
estimated 1 in 5 Australian men diagnosed with localised
disease progress to metastatic disease [6].
Most prostate cancer deaths arise as a result of disease
progression, and historically the median survival for men
with metastatic castrate-resistant prostate cancer has been
less than 2 years. The relatively recent availability of new
agents for advanced disease has provided greater hope of
cancer control for these men as trials indicate improved
survival time [7]. However, the reality is that advanced
prostate cancer is an incurable disease, and for many men,
their disease progression is associated with more frequent
healthcare interventions due to increasing morbidities from
disease and treatments [8], diminished quality of life [9],
increased psychological burden [10] and an increased risk
of suicide [11, 12].
To date no randomised controlled trials have reported
interventions to improve psychological outcomes for men
with advanced prostate cancer, with clinicians relying on
studies in men with localised disease for practice recom-
mendations [13]. Given that the psychological challenges
of advanced versus localised disease will differ (i.e. hope
for cure vs. knowledge of progression), this extrapolation is
likely inappropriate. In developing psychological inter-
ventions for such men, a first step is to consider what
modifiable variables might be relevant therapeutic targets
in a context where disease is progressive and the future
highly threatened. We propose that psychological flexibil-
ity may be important for men confronting the novel,
complex and uncertain challenges of advanced prostate
cancer. Psychological flexibility can be broadly defined as
the ability to shift mindsets in the face of changing and
challenging situational demands. This includes being more
aware of and able to accommodate, rather than deny or
distract from, unpleasant emotions and physical morbidi-
ties and from this guide ones thoughts and actions in a
constructive direction [14]. Psychological flexibility is a
high level and overarching construct that includes both
acceptance and mindfulness, with these processes proposed
as relevant to both clinical and general populations [15]. At
its centre is an interaction between psychological content,
the present moment and chosen values. Mindfulness is a
key and core component that speaks to the cognitive fusion
and experiential avoidance that is proposed to contribute to
psychological inflexibility [16]. In both laboratory and
clinical settings, greater psychological flexibility has been
found to be linked to more positive psychological out-
comes. Finally, psychological flexibility is proposed to be
stable over time, but importantly appears to be amenable to
psychological intervention and as such a potential inter-
vention target [17].
Interventions to encourage psychological flexibility, and
in particular mindfulness facets or skills, are increasingly
being applied in cancer populations as a psychotherapeutic
approach to improving adjustment after cancer. Mindful-
ness approaches aim to lead the person to be less reactive to
difficult experiences and to approach equanimity regarding
the illness experience [18]. These approaches assume
therefore a connection between these psychological facets
and a person’s psychological outcomes and quality of life.
However, to our knowledge no research to date has tested
this assumption in men with prostate cancer, and hence it is
unknown empirically whether the facets of mindfulness are
related to these patients’ adjustment outcomes. Accord-
ingly, the present study aimed to describe psychological
distress and quality of life in men with advanced prostate
cancer and examine the influence of mindfulness on these
outcomes.
Patients and methods
The present study utilised baseline data from an Australian
randomised controlled trial of a mindfulness intervention
for men with advanced prostate cancer [19]. Eligible par-
ticipants were men with metastatic prostate cancer or
castration-resistant biochemical progression who were
referred to the trial by their treating medical specialist.
Other eligibility criteria included: ability to read and speak
English; no history of head injury, dementia or current
psychiatric illness; and no concurrent cancer. All partici-
pants provided written informed consent. The trial received
approval from the Griffith University Human Research
Ethics Committee and the human research ethics commit-
tees of participating hospitals across Australia. Further
detail about this trial is provided in Chambers et al. [19].
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Sociodemographic information was collected in a tele-
phone interview. Trained researchers used a data collection
protocol to obtain clinical, disease and treatment informa-
tion through medical records review. Psychosocial mea-
sures were completed by participants via mailed self-
administered questionnaires. These measures are outlined
below.
Mindfulness facets
The 39-item Five Facet Mindfulness Questionnaire
(FFMQ) measures engagement with the principles of
mindfulness and contains five subscales: observing or
noticing ones reaction; being able to describe this reaction;
acting with awareness; non-judging of inner experience;
and non-reactivity to inner experience [20]. Items were
scored 1 (never or very rarely true) to 5 (very often or
always true) and summed to create subscale scores with
higher scores indicating greater engagement with each
principle or facet (score range for observing, describing,
acting with awareness, non-judging of inner experience
8–40; non-reactivity to inner experience 7–35). Internal
reliability was acceptable for subscales (a = 0.78–0.90)
and the total scale (a = 0.86).
Health-related quality of life
The 39-item Functional Assessment of Cancer Therapy-
Prostate (FACT-P) assesses men’s perceived global quality
of life across five domains: physical, social/family, emo-
tional, functional well-being and prostate cancer-specific
concerns [21]. For this study, items were scored 0 (not at
all) to 5 (very much) and averaged to create subscale
scores, with these subscale scores then summed to create a
global quality of life score (score range 0–156). Higher
scores indicated greater perceived quality of life
(a = 0.91). The average FACT-P total score for men with
advanced disease was reported by Esper et al. as 109.8
[21].
Psychological distress
The Brief Symptom Inventory-18 (BSI-18) provides a
global measure of current psychological distress with
subscale scores for anxiety, depression and somatisation
[22]. In the current study, the 18 items were scored 0 (not
at all) to 4 (extremely) and summed to create a Global
Severity Index (GSI) with higher scores indicating greater
distress (score range 0–72; a = 0.91). Raw scores were
transformed into standardised t scores to determine the
proportion of men who met the criteria for caseness.
Caseness has been reported as a standardised t score of 57
or above on the GSI or any two subscales in men with
cancer [23]. This cut-off score was used to indicate the
percentage of men with clinical psychological distress in
this sample.
Cancer-specific distress
The 15-item Impact of Events Scale (IES) measures men’s
cancer-specific distress and contains two subscales: intru-
sive symptoms and avoidance symptoms [24]. Items were
scored 0 (not at all) to 5 (extremely) and summed to create
an overall score with higher scores indicating greater dis-
tress (score range 0–75; a = 0.93). A score of 20 or above
on either the intrusive or avoidance symptoms subscale
was used to calculate the proportion of men with clinical
cancer-specific distress, and this is in line with the cut-off
score used for the IES in advanced cancer patients [25].
Statistical analyses
Three hierarchical regressions examined the factors asso-
ciated with quality of life, cancer-specific distress and
psychological distress. Variables were entered into the
regression in the following order: Step 1: sociodemo-
graphic and clinical characteristics (age, marital status,
education level, the presence of a limiting comorbidity,
time since diagnosis) and Step 2: the five facets of the
FFMQ (observing, describing, acting with awareness, non-
judging of inner experience, non-reactivity to inner expe-
rience). Categorical variables of marital status (1 married/
de facto; 0 single), education level (1 tertiary; 0 high school
or less) and the presence of a limiting comorbidity (1 yes; 0
no) were coded dichotomously for the analysis. Pairwise
deletion was used for missing data.
Results
Patients
Between September 2012 and January 2015, 472 patients
were referred to participate in the study; of these 190
completed the assessment (61 were ineligible and 221
declined to participate). Thirteen of the 190 men self-re-
ferred to the project team in response to media about the
project and were assessed for eligibility prior to recruit-
ment. The sociodemographic characteristics, self-reported
health status and prostate cancer history are reported in
Table 1. For prostate cancer history, medical record data
were not obtainable for all patients and are reported
accordingly.
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Psychological care and support
Thirty-nine per cent of men met the criteria for clinical
psychological distress as indicated by the BSI-18 [23].
Eighteen per cent of men met the criteria for clinical
cancer-specific distress as indicated by the IES [25].
However, only 6 % of participants were currently receiving
psychological care (psychiatrist, 2 %; psychologist, 4 %),
and 11 % were taking medication for depression or anxi-
ety. Thirty-four per cent had accessed some psychological
care in the past (psychiatrist 10 %; psychologist 12 %;
counsellor 14 %).
In the 6 months prior to the study, 56 % of men had
received support for prostate cancer and this was pre-
dominantly from prostate cancer support groups (26 %),




health status and prostate cancer
history (n = 190)
Variable
Age 70.8 years (8.7 years)
Married or de facto relationship 75 %
Retired 68 %
Born in Australia 66 %
University or college degree 66 %
BMI
Overweight range 47 %
Obese range 28 %
Smoking history
Ex-smoker 45 %
Current smoker 7 %
Comorbid health conditions
Any condition 92 %
Back pain 59 %
Osteoarthritis or degenerative arthritis 54 %
High blood pressure 48 %
Depression or anxiety 27 %
Heart disease 22 %
Diabetes 18 %
Lung disease 11 %
At least one condition limited current activities 58 %
Time since prostate cancer diagnosis 6 years (4.9 years)





PSA levelc 50.6 ng/mL* (106.3 ng/mL)
Prostate cancer treatmentd
Androgen deprivation therapy 97 %
Radiation therapy 69 %
Prostatectomy 44 %
Chemotherapy 31 %
Active surveillance 4 %
Watchful waiting 4 %
Orchidectomy 2 %
Values in parentheses are standard deviations for continuous variables
* PSA range = 0.01–588.9 ng/mL; PSA median = 7.94 ng/mL
a n = 114; b n = 83; c n = 160; d n = 171
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doctor (26 %), or the Internet (26 %). Men also received
support from family or friends (17 %), a nurse or other
health professional (16 %) and prostate cancer related
newsletters (13 %). Although 58 % of participants reported
previous use of the Internet for information about their
prostate cancer, only 7 % used this to access online support
groups or other social services.
Quality of life
Table 2 provides the descriptive statistics and inter-corre-
lations for all variables in the main analyses. Sociodemo-
graphic and clinical characteristics entered at Step 1 of the
hierarchical regression explained 13.3 % of the variance in
quality of life, F(5, 149) = 4.58, p\ 0.001. Limitation by
comorbidity was the only significant predictor of quality of
life at this step (B = -13.44, SE = 3.09, b = -.33,
p\ 0.001). The addition of the five facets of mindfulness
in Step 2 significantly increased the explained variance by
30.4 %, F(5, 144) = 15.52, p\ 0.001. Limitation by
comorbidity remained a significant predictor of quality of
life at this step contributing 2.8 % unique variance. Of the
five facets acting with awareness and non-judging of inner
experience were the only significant predictors of quality of
life, contributing 3.1 and 9.3 % unique variance, respec-
tively. Both of these facets had a positive relationship with
quality of life (Table 3).
Cancer-specific distress
In Step 1, sociodemographic and clinical characteristics
explained 8.2 % of the variance in cancer-specific distress,
F(5, 148) = 2.66, p = 0.02. Limitation by comorbidity
was the only significant predictor of cancer-specific distress
at this step (B = 7.14, SE = 2.59, b = .22, p\ 0.01). The
addition of the five facets of mindfulness in Step 2 sig-
nificantly increased the explained variance by 42.8 %, F(4,
143) = 24.98, p\ 0.001. At this final step, non-judging of
inner experience was the only significant predictor of
cancer-specific distress and contributed 18.3 % of unique
variance. Greater non-judging was related to lower cancer-
specific distress. Limitation by comorbidity was no longer
significant at the second step with the addition of the
mindfulness facets to the model (Table 4).
Psychological distress
Sociodemographic and clinical characteristics in Step 1
explained 10.2 % of the variance in psychological distress,
F(5, 148) = 3.36, p\ 0.01. Limitation by comorbidity
was the only significant predictor of psychological distress
at this step (B = 6.11, SE = 1.65, b = .29, p\ 0.001). In
Step 2, the addition of the five facets of mindfulness
significantly increased the explained variance by 41.3 %,
F(5, 143) = 24.33, p\ 0.001. Four out of the five facets
were significant predictors of psychological distress at this
final step. Non-judging of inner experience contributed the
most unique variance (10 %) followed by acting with
awareness (4.5 %), non-reactivity to inner experience
(3.2 %) and observing (1.6 %). Each facet had a negative
relationship with psychological distress with the exception
of observing which had a positive relationship with dis-
tress. Limitation by comorbidity was no longer significant
at the second step with the addition of the mindfulness
facets to the model (Table 5).
Discussion
Many of the men in this study reported high levels of
psychological distress, with health-related quality of life
similar to previous research with men with advanced
prostate cancer [21]. Importantly, three key psychological
mechanisms or mindfulness facets were associated with
better outcomes: awareness, non-judgement and non-reac-
tivity. Evidence suggests that people who judge their
(especially negative) experiences can end up in a rumina-
tive loop of ‘‘why am I feeling this way’’ which ironically
has the effect of worsening distress [26]. Our results sup-
port this contention and suggest that interventions that
promote awareness paired with non-judgement and non-
reactivity may be useful in the setting of advanced prostate
cancer. With regard to intervention research, to date a few
preliminary studies have reported applying mindfulness
approaches with men with prostate cancer. One single-arm
trial of mindfulness-based stress reduction groups with 49
breast cancer patients and 10 men with localised prostate
cancer found post-intervention improvements in quality of
life and stress symptoms [27], with benefits maintained
over time [28]. In a more recent study, men with advanced
prostate cancer who participated in a mindfulness-based
cognitive intervention targeting self-awareness, non-
judgement and acceptance, reported moderate to large
improvements in anxiety and fear of cancer recurrence
[29]. In the present study, non-judging of inner experience
demonstrated the strongest effect across both quality of life
and psychological distress and this may be of particular
relevance given masculine values around stoicism in the
face of adversity that may exacerbate distress and isolation
in a chronic illness [30]. Specifically, as cancer progresses
and fears and concerns about the future naturally arise, a
stoic approach may become difficult to maintain. Hence the
development of a less judgemental and more flexible
approach to coping may be crucial for men facing
advanced prostate cancer. These are important and novel
findings.
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Despite high distress, most men were currently not
receiving psychological care. This is consistent with pre-
vious research showing that men with prostate cancer often
report unmet psychological needs [31] and again reinforces
the need for action to detect men with high distress and
provide targeted intervention [32]. Taking into account the
apparent strong role of mindfulness facets across both QOL
and distress, acceptance focussed approaches such as
mindfulness-based cognitive therapies may be indicated
[33]. Uptake of support groups was high in this cohort and
was more accessed than professional psychological care.
This may relate at least in part to the social isolation that
can be experienced when cancer has advanced leading a
person to seek support by connecting with others in a
similar situation [34, 35]. These approaches appear worthy
of future research.
It is noteworthy that being limited by comorbid condi-
tions was an independent predictor of HRQOL, but not
cancer-specific or global distress. This may be due to the
fact that the HRQOL measure captures limitations in social
and physical functioning which might be directly due to
comorbid conditions, particularly arthritis and back pain
that were highly prevalent in this population. The finding
that physical limitations imposed by comorbid conditions
were not strong predictors of distress after psychological
flexibility was entered into the models suggests that this
flexibility may mediate the distressing effects of other
physical health problems, not just prostate cancer.
Limitations of the present study include the cross-sec-
tional design such that causality cannot be inferred. How-
ever, the inclusion of modifiable psychological variables
using well-validated assessment measures is novel, and the
use of a relatively large national sample is a strength.
Future longitudinal research is needed to test if these
relationships persist over time. As well, the participation
rate was only 46 % with men in the study reporting high
levels of education. It may be that men who did not par-
ticipate differed in other background or clinical charac-
teristics as well as their levels of distress and as a result our
Table 3 Final step of hierarchical regression predicting quality of
life (n = 155)
Predictors B SE b
Sociodemographic and clinical characteristics
Age -.03 .15 -.01
Marital status .37 3.00 .01
Education -.83 2.73 -.02
Limited by a comorbidity -7.27 2.74 -.18*
Time since diagnosis .37 .26 .09
Mindfulness facets
Observing .09 .26 .03
Describing .16 .24 .05
Acting with awareness .77 .27 .23*
Non-judging of inner experience 1.10 .23 .39**
Non-reactivity to inner experience .36 .27 .11
At the final step, the overall model was significant and explained
43.7 % of the variance in quality of life, F(10, 144) = 11.17,
p\ 0.001
* p\ 0.05; ** p\ 0.001
Table 4 Final step of hierarchical regression predicting cancer-
specific distress (n = 154)
Predictors B SE b
Sociodemographic and clinical characteristics
Age -.12 .12 -.06
Marital status .73 2.30 .02
Education 3.57 2.07 .11
Limited by a comorbidity .81 2.08 .02
Time since diagnosis -.20 .20 -.06
Mindfulness facets
Observing .05 .19 .02
Describing -.21 .18 -.09
Acting with awareness -.39 .21 -.15a
Non-judging of inner experience -1.25 .17 -.55**
Non-reactivity to inner experience -.03 .21 -.01
At the final step, the overall model was significant and explained
51.0 % of the variance in cancer-specific distress, F(10,
143) = 14.89, p\ 0.001
* p\ 0.05; ** p\ 0.001; a p = 0.057
Table 5 Final step of hierarchical regression predicting psychologi-
cal distress (n = 154)
Predictors B SE b
Sociodemographic and clinical characteristics
Age -.06 .08 -.05
Marital status -1.08 1.46 -.04
Education .23 1.33 .01
Limited by a comorbidity 1.88 1.33 .09
Time since diagnosis -.01 .13 -.00
Mindfulness facets
Observing .27 .12 .17*
Describing -.12 .11 -.08
Acting with awareness -.48 .13 -.28**
Non-judging of inner experience -.60 .11 -.40**
Non-reactivity to inner experience -.41 .13 -.23*
At the final step, the overall model was significant and explained
51.5 % of the variance in psychological distress, F(10, 143) = 15.16,
p\ 0.001
* p\ 0.05; ** p\ 0.001
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study may well underrepresent levels of distress in this
vulnerable patient group. Finally, we note that the observed
facet was associated with greater distress, a direction of
effect consistent with earlier research suggesting this sub-
scale may not capture the quality of noticing one’s expe-
rience that is central to mindfulness-based approaches [20].
Future research in the cancer context is needed to expand
assessments of psychological flexibility beyond mindful-
ness to include other processes, such as values exploration
and committed action and from this fine-tune potential
therapy targets [16].
In conclusion, several facets of mindfulness may hold
promise as therapeutic targets to reduce psychological
distress and improve QOL in men with advanced prostate
cancer. Future longitudinal descriptive research is needed
to examine the influence of not only psychological flexi-
bility in its broader definition, but also other relevant
constructs such as masculinity [36]. This would assist both
practitioners and researchers to better understand the
dynamic of how men adjust and learn to live with serious
and chronic illness. Finally, larger randomised controlled
trials controlled trials are needed to move knowledge for-
ward in the effectiveness of psychological interventions for
men with cancer.
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